Principle Investigators and Senior Personnel:
The Multimodal Treatment Study of Children with ADHD (MTA) was a National Institute of Mental Health (NIMH) cooperative agreement randomized clinical trial, continued under an NIMH contract as a follow-up study and finally under a National Institute on Drug Abuse (NIDA) contract.
Collaborators from NIMH:
Benedetto Vitiello, M.D. (Child & Adolescent Treatment and Preventive Interventions Research Branch)
Joanne B. Severe, M.S. (Clinical Trials Operations and Biostatistics Unit, Division of Services and Intervention Research)
Peter S. Jensen, M.D. (currently at REACH Institute and Mayo Clinic)
L. Eugene Arnold, M.D., M.Ed. (currently at Ohio State University)
Kimberly Hoagwood, Ph.D. (currently at Columbia)
Previous contributors from NIMH to the early phases:
John Richters, Ph.D. (currently at National Institute of Nursing Research)
Donald Vereen, M.D. (currently at NIDA)
University of California, Berkeley/San Francisco:
Stephen P. Hinshaw, Ph.D. (Berkeley)
Glen R. Elliott, Ph.D., M.D. (San Francisco)
Duke University:
Karen C. Wells, Ph.D.
Jeffery N. Epstein, Ph.D. (currently at Cincinnati Children's Hospital Medical Center)
Desiree W. Murray, Ph.D.
Previous Duke contributors to early phases:
C. Keith Conners, Ph.D. (former PI)
John March, M.D., M.P.H.
University of California, Irvine:
James Swanson, Ph.D.
Timothy Wigal, Ph.D.
Previous contributor from UCLA to the early phases:
Dennis P. Cantwell, M.D. (deceased)
New York University:
Howard B. Abikoff, Ph.D.
Montreal Children's Hospital/ McGill University:
Lily Hechtman, M.D.
New York State Psychiatric Institute/Columbia University/Mount Sinai Medical Center:
Laurence L. Greenhill, M.D. (Columbia)
Jeffrey H. Newcorn, M.D. (Mount Sinai School of Medicine)
University of Pittsburgh:
Brooke Molina, Ph.D.
Betsy Hoza, Ph.D. (currently at University of Vermont)
William E. Pelham, Ph.D. (PI for early phases, currently at Florida International University)
Follow-up phase statistical collaborators:
Robert D. Gibbons, Ph.D. (University of Illinois, Chicago)
Sue Marcus, Ph.D. (Mt. Sinai College of Medicine)
Kwan Hur, Ph.D. (University of Illinois, Chicago)
Original study statistical and design consultant:
Helena C. Kraemer, Ph.D. (Stanford University)
Collaborator from the Office of Special Education Programs/US Department of Education:
Thomas Hanley, Ed.D.
Collaborator from Office of Juvenile Justice and Delinquency Prevention/Department of Justice:
Karen Stern, Ph.D.
Additional investigators for Neuroimaging Substudy:
Leanne Tamm, Ph.D., PI (Cincinnati Children's Hospital Medical Center)
James Bjork, Ph.D. (Division of Clinical Neuroscience and Behavioral Research, NIDA)
Daniel Mathalon, M.D., Ph.D. (UC San Francisco)
Allen Song, Ph.D. (Duke)
Bradley Peterson, M.D. (Columbia)
Steven Potkin, M.D. (UC Irvine)
Claudia Buss, Ph.D. (UC Irvine)
Katerina Velanova, Ph.D. (Pittsburgh)
Neuroimaging Consultants:
Susan Tapert, Ph.D.(UC San Diego)
Joshua Kuperman, Ph.D. (UC San Diego)
BJ Casey, Ph.D. (Sackler Institute, Cornell)
Leah Sommerville, Ph.D. (Sackler Institute, Cornell)
Krista Medina, Ph.D. (University of Milwaukee)
Neuroimaging Analysis and Interpretation:
Terry Jernigan, Ph.D. (UC San Diego)
Anders Dale, Ph.D. (UC San Diego)
F. Xavier Castellanos, M.D. (New York University)
Clare Kelly, Ph.D. (New York University)
Acknowledgements:
Data used in the preparation of this article were obtained from the NIDA MTA Neuroimaging Study database. The study was launched in 2010 by the National Institute on Drug Abuse (NIDA) as a 2-year project of the American Recovery and Reinvestment Act. The primary goal of the study has been to create a data resource of highly standardized magnetic resonance imaging (MRI) data and neuropsychological assessments for a cohort of individuals participating in the Multimodal Treatment Study for ADHD (MTA) with and without exposure to cannabis. The scientific aim of the project is to increase understanding of the impact of substance use on brain functioning in individuals with and without a childhood history of ADHD. Data used in preparation of this article were obtained from the NIDA MTA Neuroimaging Study database. As such, the investigators within the NIDA MTA Neuroimaging group contributed to the design and implementation of the study and/or provided data but did not participate in analysis or writing of this report.
This dataset includes:
USAGE AGREEMENT
Creative Commons License: Attribution - Non-Commercial
Funding
Data collection and sharing for this project was funded by the NIDA MTA Neuroimaging Study (National Institute on Drug Abuse Grant Contract #: HHSN271200800009C).
Data Release Table
Note: This data is archived in groups of subjects. If you wish to download individual subjects data or a different selection than the archived files please see here for instruction.
Raw Data
Preprocessed Data
Parcellated Data
SV format, each subjects file contains data from all 8 pipelines. Column labels index the roi and the pipeline name.
Pipeline 1: ANTS Registered, No Scrubbing, No Global Signal Regression
Pipeline 2: ANTS Registered, No Scrubbing, With Global Signal Regression
Pipeline 3: ANTS Registered, With Scrubbing, No Global Signal Regression
Pipeline 4: ANTS Registered, With Scrubbing, With Global Signal Regression
Pipeline 5: FNIRT Registered, No Scrubbing, No Global Signal Regression
Pipeline 6: FNIRT Registered, No Scrubbing, With Global Signal Regression
Pipeline 7: FNIRT Registered, With Scrubbing, No Global Signal Regression
Pipeline 8: FNIRT Registered, With Scrubbing, With Global Signal Regression
